BSEInsider Trading / SAST22 Oct 2026 · 22 Oct 2026, 06:28 pm
Update on Trading Window Closure period
Natco Pharma Ltd · 524816
✦ AI Summary
Natco Pharma Ltd has closed its trading window for all directors, designated persons, and connected individuals from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ended September 30, 2026. The trading window will reopen from October 23, 2026, to October 28, 2026, to enable the credit of rights equity shares in demat accounts of allottees.
Analysis Scores
Earnings Impact5/10
Growth Catalyst5/10
Governance Concern2/10
Regulatory Risk2/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Natco Pharma Ltd - 524816 - Closure of Trading Window
Attachments (1)
📄pdf
Download →
db9499fe-4fdf-46a7-afa4-9bfd4eef74c8.pdf
View document text
22nd October, 2026
M/s. BSE Limited M/s. National Stock Exchange of India Ltd
Mumbai 400 001 Mumbai 400 051
Scrip Code: 524816 Scrip Code: NATCOPHARM
Dear Sir/Madam,
Sub:- Trading Window
Ref: Our letter dated 30th September, 2026 regarding the closure of the Trading Window.
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the Company’s
Code of Conduct, we wish to inform you that the Trading Window for dealing in the securities
of the Company was closed for all Directors, Designated Persons, their immediate relatives,
and all other connected persons with effect from October 1, 2026 to till 48 hours after the
declaration of the Unaudited Financial Results of the Company for the quarter ended
September 30, 2026.
Further, we wish to inform that the Company is in the process of Rights Issue Allotment.
In this regard, we hereby inform you that the trading window will remain open from 23rd
October, 2026 to 28th October, 2026 to enable the credit of Rights Equity shares in the demat
accounts of the respective allotees (i.e., Directors, Designated Persons, their immediate
relatives, and all other connected persons) who got allotment of shares in the Rights Issue.
This is for your information and records.
Thanking you
Yours faithfully
For NATCO Pharma Limited
Ch. Venkat Ramesh
Company Secretary &
Compliance Officer